Sen. Grassley Questions FDA’s Response To Acetaminophen Concerns
This article was originally published in The Tan Sheet
Executive Summary
Sen. Chuck Grassley, R-Iowa, asks FDA to account for its lag time in reacting to acetaminophen safety concerns in a March 20 letter to Commissioner Andrew von Eschenbach
You may also be interested in...
McNeil Sponsors “Answers In The Aisles” Web Site For OTC Analgesic Safety
McNeil Consumer Healthcare is launching a Web-based educational program to educate consumers on OTC medicine safety in the wake of an FDA proposed rule to implement stronger label warnings for nonprescription pain relievers
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
CHPA Campaign Asks Consumers To “CHEC” Their OTC Know-How
Results of a survey of OTC consumers revealing that one in six adults takes three or more pills at a single time were a driving factor behind CHPA's establishment of the Consumer Healthcare Education Center